FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Beck Joanne T.						2. Issuer Name and Ticker or Trading Symbol Orchard Therapeutics plc [ORTX]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
					3 [) ata	of Earl	ieet Tranc	action (Mc	nth/D	av/Vear)							·	
(Last)	,	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 01/24/2024								below)	give title	ive title Other below		pecify		
C/O ORCHARD THERAPEUTICS PLC						4. If Amendment, Date of Original Filed (Month/Day/Year)							6. In	6. Individual or Joint/Group Filing (Check Applicable					
245 HAMMERSMITH ROAD						,,,,,,,,							1 1	Line)					
														X Form filed by One Reporting Person					
(Street)														Form file Person	ed by More	than	One Reporti	ing	
LONDO	LONDON X0 W6 8PW			_								1 013011							
				Rι	Rule 10b5-1(c) Transaction Indication														
(City)	(S	itate)	(Zip)																
					$ \sqcup$	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Та	ble I - Nor	n-Deriv	/ativ	e Se	curi	ties Ac	quired,	Dis	posed o	f, or Be	neficially	Owned					
1. Title of	Security (Inst	tr. 3)		2. Trans	action				3.			ties Acquir						. Nature of	
Date (Month/D									Transaction Disposed Of (D) (Instr. 3, 4 Code (Instr. 5)			tr. 3, 4 and	Securities Beneficial	lly	(D) or	Indirect B	ndirect Beneficial		
			(Month/Day/Year)								Owned Fo	llowing (I) (In			Ownership Instr. 4)				
										v	Amount	Amount (A) or Pr		Transaction (Instr. 3 and	ion(s)			·	
0 tr							/2024			 	 		-	· /			Б		
Ordinary Shares ⁽¹⁾ 01/24/					/2024		D ⁽²⁾⁽³⁾		9,294 D		(2)(3)	0			D				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
(e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of 2. 3. Transaction 3A. Deemed 4.						5. Numbe			6. Date E	6. Date Exercisable and 7. Title and Amo			d Amount	8. Price of	9. Number of		10.	11. Nature	
Derivative Conversion Date Execution Date,					ansact	tion			Expiration Date of Securities (Month/Day/Year) Underlying				Derivative Security	derivative Securities		Ownership Form:	of Indirect Beneficial		
(Instr. 3)	Price of	(Month/Day/Tear)	(Month/Day/\			Acquired (A)			Derivative Secu					(Instr. 5)	Beneficial		Direct (D)	Ownership	
	Derivative Security						or Disposed of (D) (Instr. 3, 4 and 5)		(Instr. 3 and 4)				nd 4)		Owned Following		or Indirect (I) (Instr. 4)	(Instr. 4)	
				<u> </u>										ļ	Reported Transaction(s)				
													Amount		(Instr. 4)	()			
						v	 	(m)	Date		Expiration		Number						
					ode	<u> </u>	(A)	(D)	Exercisal	DIE L	Date	Title	of Shares						
Stock Option	00.475	01/24/2024			(2)(3)			46,000	(4)		06/06/2022	Ordinary	46.000	20.00			D		
(Right to Buy)	\$0.475	01/24/2024		l D	(2)(3)			46,000	(4)	- 1	06/06/2032	Shares ⁽¹⁾	40,000	\$0.00	0		D		
	<u> </u>				-					+									
Stock Option	\$ 0.495	01/24/2024			(2)(3)			105.000	(4)		06/13/2033	Ordinary	105.000	\$0.00	0		D		
(Right to	φυ. 4 93	01/24/2024		I D	,,,,,			103,000	(-)	- 1	10/13/2033	Shares ⁽¹⁾	103,000	φυ.υυ	"		D		

Explanation of Responses:

- 1. The ordinary shares, nominal value GBP 0.10 per share (the "Ordinary Shares") may be represented by American Depositary Shares ("ADSs"), each of which currently represents ten Ordinary Shares.
- 2. On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company ("KKC") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) \$1.60 in cash, without interest (the "Cash Consideration"), and (b) one contractual contingent value right (each, a "CVR"), each representing the right to receive a contingent payment of \$0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC.
- 3. (continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) \$16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023.
- 4. Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR.

/s/ Frank Thomas, Attorney-in-

01/24/2024

Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.